Duman Turebekov

Duman Turebekov

Auto-generated profile, based on publicly available information

Duman Turebekov

Department of Internal Medicine, Astana Medical University, Astana, Kazakhstan

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2020 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
AGAbduzhappar Gaipov
Abduzhappar Gaipov
ZUZhandos Utegulov
Zhandos Utegulov
RBRostislav Bukasov
Rostislav Bukasov
DTDuman Turebekov
Duman Turebekov
PTPavel Tarlykov
Pavel Tarlykov
ASAlisher Sultangaziyev
Alisher Sultangaziyev
Background: Proteinuria is a major marker of chronic kidney disease (CKD) progression and the predictor of cardiovascular mortality. The rapid development of renal failure is expected in those patients who have higher level of proteinuria however, some patients may have slow decline of renal function despite lower level of urinary protein excretion. The different mechanical (visco-elastic) and chemical properties, as well as the proteome profiles of urinary proteins might explain their tubular toxicity mechanism. Brillouin light scattering (BLS) and surface enhanced Raman scattering (SERS) spectroscopies are non-contact, laser optical-based techniques providing visco-elastic and chemical property information of probed human biofluids. We proposed to study and compare these properties of urinary proteins using BLS and SERS spectroscopies in nephrotic patient and validate hybrid BLS-SERS spectroscopy in diagnostic of urinary proteins as well as their profiling. The project ultimately aims for the development of an optical spectroscopic sensor for rapid, non-contact monitoring of urine samples from patients in clinical settings. Methods: BLS and SERS spectroscopies will be used for non-contact assessment of urinary proteins in proteinuric patients and healthy subjects and will be cross-validated by Liquid Chromatography-Mass Spectrometry (LC-MS). Participants will be followed-up during the 1 year and all adverse events such as exacerbation of proteinuria, progression of CKD, complications of nephrotic syndrome, disease relapse rate and inefficacy of treatment regimen will be registered referencing incident dates. Associations between urinary protein profiles (obtained from BLS and SERS as well as LC-MS) and adverse outcomes will be evaluated to identify most unfavored protein profiles. Discussion: This prospective study is focused on the development of non-contact hybrid BLS - SERS sensing tool and its clinical deployment for diagnosis and prognosis of proteinuria. We will identify the most important types of urine proteins based on their visco-elasticity, amino-acid profile and molecular weight responsible for the most severe cases of proteinuria and progressive renal function decline. We will aim for the developed hybrid BLS - SERS sensor, as a new diagnostic & prognostic tool, to be transferred to other biomedical applications. Trial registration: The trial has been approved by ClinicalTrials.gov (Trial registration ID NCT04311684). The date of registration was March 17, 2020.

25 October 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
AGAbduzhappar Gaipov
Abduzhappar Gaipov
ZMZhalaliddin Makhammajanov
Zhalaliddin Makhammajanov
ZDZhanna Dauyey
Zhanna Dauyey
ZMZhannur Markhametova
Zhannur Markhametova
KMKamilla Mussina
Kamilla Mussina
MKMehmet Kanbay
Mehmet Kanbay
Proteinuria is a risk factor for chronic kidney disease (CKD) progression and associated complications. However, there is insufficient information on individual protein components in urine and the severity of CKD. We aimed to investigate urinary proteomics and its association with proteinuria and kidney function in early-stage CKD and in healthy individuals. A 24 h urine sample of 42 individuals (21-CKD and 21-healthy individuals) was used for mass spectrometry-based proteomics analysis. An exponentially modified protein abundance index (emPAI) was calculated for each protein. Data were analyzed by Mascot software using the SwissProt database and bioinformatics tools. Overall, 298 unique proteins were identified in the cohort; of them, 250 proteins belong to the control group with median (IQR) emPAI 39.1 (19–53) and 142 proteins belong to the CKD group with median (IQR) emPAI 67.8 (49–117). The level of 24 h proteinuria positively correlated with emPAI (r = 0.390, p = 0.011). The emPAI of some urinary proteomics had close positive (ALBU, ZA2G, IGKC) and negative (OSTP, CD59, UROM, KNG1, RNAS1, CD44, AMBP) correlations (r < 0.419, p < 0.001) with 24 h proteinuria levels. Additionally, a few proteins (VTDB, AACT, A1AG2, VTNC, and CD44) significantly correlated with kidney function. In this proteomics study, several urinary proteins correlated with proteinuria and kidney function. Pathway analysis identified subpathways potentially related to early proteinuric CKD, allowing the design of prospective studies that explore their response to therapy and their relationship to long-term outcomes.
1

26 June 2023 in Digital Diagnostics
Verified
Journal Article
Open access
PDF file
ETElvira Zh. Tanirkhanova
Elvira Zh. Tanirkhanova
LZLazzat Zhussupbekova
Lazzat Zhussupbekova
DTDuman K. Turebekov
Duman K. Turebekov
BZBayana K. Zhakeyeva
Bayana K. Zhakeyeva
TBTamilla T. Baimukanova
Tamilla T. Baimukanova
ЖКЖакеева Баяна Каирбековна
Жакеева Баяна Каирбековна
BACKGROUND: In recent years, an increasing tendency of oncopathology in patients with chronic kidney disease (CKD) was observed. Clinical data demonstrate an increased risk of malignization in patients with decreased renal function. The cohort study (2022) reported a cumulative incidence of cancer in nephrology patients ranging from 10.8% to 15.3%. A high percentage of stage IV cancers were detected in patients with CKD at the time of diagnosis. In 2022, the American Association for Cancer Research published the results of a Mendelian Randomization Study examining the causal relationship between CKD and the risk of developing 19 local cancers, including renal cell cancer, cervical cancer, leukemia, and colorectal cancer. Several studies found a direct correlation between a decreased glomerular filtration rate and the development of oncopathologies. Therefore, cancer awareness is important in the management of patients with CKD. In patients with end-stage chronic renal disease (ESRD) who are on hemodialysis, X-ray diagnosis with iodine-containing radiopaque agents is possible without additional risk of kidney damage. AIM: To demonstratу the role of computed tomography (CT) in the diagnosis of oncopathology in a patient with CKD to attract the attention of physicians to the importance of using advanced diagnostic techniques in patients with CKD. METHODS: A clinical case of a 32-year-old patient M. who was hospitalized in the Therapeutic Department of Multidisciplinary City Hospital No. 2 in Astana was presented. RESULTS: A patient with ESRD resulting from chronic glomerulonephritis in a hypertensive form complained of dyspnea at rest, cough with difficult sputum, right thoracic pain, general weakness, and weight loss of 8 kg in 1 month. Past medical history showed that the patient was on alternate program hemodialysis for 4 years. Deterioration occurred within 3 months. The patient was examined at the place of residence. CT scan showed signs of tuberculosis of the upper right lobe (?) and lymphadenopathy of intrathoracic and axillary lymph nodes. A neoplasm was not excluded. The patient was consulted by a phthisiatrician, GeneXpert sputum was performed, and tuberculosis was excluded. In dynamics, ultrasound was conducted due to increasing dyspnea. Fluid accumulation in the pericardial and pleural cavities was detected. A pulmonologist assessed the situation as uremic pericarditis, pleurisy on the right side, and right-sided pneumonia in the upper lobe of unclear genesis. Antibacterial therapy was prescribed. Due to a significant deterioration of the condition, the patient went to the city hospital. At admission, respiratory failure, pain syndrome in the chest area, and marked asthenization up to cachexia were observed. Ultrasound of pleural cavities showed free fluid in the pleural cavity on the right (770 ml) and left (110 ml), whereas abdominal ultrasound revealed cavernous hemangiomas of the liver (?), echogenic suspension of the gallbladder, and splenomegaly. Echocardiography showed diffuse hypokinesis of all left ventricular walls. Grade 12 pulmonary hypertension was detected. Systolic function of the left ventricle was moderately decreased. Effusion in the pericardial cavity in the volume of 430 ml and congestion in the inferior vena cava were found. A patient with ESRD was on program hemodialysis for 4 years, which allowed the use of contrast-enhanced X-ray imaging techniques without the risk of additional renal damage. Contrast-enhanced chest CT showed pronounced right-sided pleurisy. Given the presence of foci of contrast agent accumulation in the structure of the parietal pleura, malignancy was not excluded (mesothelioma?). Indolent left-sided pleurisy, segmental and subsegmental compression atelectasis of the right lung, distinct edema and thickening of interlobular septa of both lungs, and single dense foci of I/II, III segments of the left lung up to 4.2 mm in diameter were detected. In addition, chronic bronchitis, pericarditis, and lymphadenopathy of subclavian, intrathoracic, and axillary lymph nodes up to 15.0 mm in diameter (malignancy not excluded) were revealed. Osteosclerosis foci of the Th3 vertebral body measuring 4.75.1 mm was observed. Contrast-enhanced abdominal and retroperineal CT scan showed a focal mass of the IVa segment of the liver measuring 17.315.916.4 mm (malignancy not excluded), chronic calculous cholecystitis, chronic pancreatitis, lymphadenopathy of intra-abdominal para-aortic and mesenteric lymph nodes up to 18.0 mm in size (malignancy not excluded), reduced size of both kidneys (contracted kidneys), and a cystic mass in the left ovary measuring 39.442.034.5 mm (35 HU). Patient was consulted by an oncologist: pleural mesothelioma? Metastasis in the liver? Consultation with a thoracic surgeon to decide on morphological verification was recommended. A biopsy was planned at the place of residence; however, morphological verification of oncopathology was not performed due to the patients lethal outcome. CONCLUSIONS: This clinical case of a patient with ESRD on hemodialysis demonstrates the importance of contrast-enhanced CT to diagnose oncopathology.

6 September 2025 in Central Asian Journal of Nephrology
Verified
Journal Article
Closed access
STSaltanat Tuganbekova
Saltanat Tuganbekova
GYGulzhan Yertlessova
Gulzhan Yertlessova
KKKairat Kabulbayev
Kairat Kabulbayev
ABAinur Botabayeva
Ainur Botabayeva
DTDuman Turebekov
Duman Turebekov
AGAbduzhappar Gaipov
Abduzhappar Gaipov
The advent of targeted complement inhibitors represents a paradigm shift in managing complement-mediated nephropathies. Integrating these therapies into healthcare systems, particularly in resource-variable settings, requires strategic planning. A national council of experts was convened in October 2024 with the purpose of obtaining a clinical expert opinion to develop practical recommendations for improving the organization and optimization of medical care for patients with C3 glomerulopathy (C3G) and IgA nephropathy (IgAN) in Kazakhstan. The council identified critical systemic gaps, including inconsistent use of renal biopsy, lack of specialized nephropathology, absence of treatment algorithms, and fragmented patient care. A consensus was reached on key recommendations for a new national clinical protocol. These include mandating pathological confirmation, creating detailed treatment and monitoring algorithms, establishing a national registry and coordination center, and investing in specialized training for healthcare professionals. The systematic framework proposed by the council provides an actionable roadmap to overcome barriers to care. This model ensures equitable patient access to novel therapies and may serve as a blueprint for other nations navigating the integration of advanced treatments into clinical practice.

1 January 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
ZMZhalaliddin Makhammajanov
Zhalaliddin Makhammajanov
KNKamila Nurlybayeva
Kamila Nurlybayeva
ZAZikrillo Artikov
Zikrillo Artikov
PTPavel Tarlykov
Pavel Tarlykov
MAMohamad Aljofan
Mohamad Aljofan
AGAbduzhappar Gaipov
Abduzhappar Gaipov
Chronic kidney disease (CKD) is a progressive condition characterized by declining renal function, with limited biomarkers to predict its progression. The early identification of prognostic biomarkers is crucial for improving patient care and therapeutic strategies. This follow-up study investigated urinary proteomics and clinical outcomes in 18 CKD patients (stages 1–3) and 15 healthy controls using liquid chromatography–mass spectrometry and Mascot-SwissProt for protein identification. The exponentially modified protein abundance index (emPAI) was used for peptide quantification. Regression analyses were used to evaluate relationships between urinary proteins and the estimated glomerular filtration rate (eGFR), adjusting for proteinuria. At baseline, 171 proteins (median emPAI 86) were identified in CKD patients, and 271 were identified (median emPAI 47) in controls. At follow-up, 285 proteins (median emPAI 44.8) were identified in CKD patients, and 252 were identified (median emPAI 34.2) in controls. FBN1 was positively associated with eGFR, while FETUA showed a significant negative correlation at baseline. At follow-up, VTDB shifted from a negative baseline to a positive association with eGFR over time. CD44 and FBN1 shifted from a positive baseline to a negative association over time. These findings highlight VTDB, FBN1, and CD44 as potential prognostic biomarkers, providing insights into CKD progression and therapeutic targets.

7 October 2026 in Central Asian Journal of Nephrology
Verified
Journal Article
Open access
PDF file
DTDuman Turebekov
Duman Turebekov
Introduction: Obstetric thrombotic microangiopathies (TMAs) are rare but potentially life-threatening disorders that include HELLP syndrome, thrombotic thrombocytopenic purpura, and atypical hemolytic uremic syndrome (aHUS). Their overlapping clinical features often complicate timely diagnosis. Differentiating HELLP syndrome from aHUS is particularly challenging when TMA persists and acute kidney injury (AKI) progresses after delivery. Early recognition of aHUS is crucial because targeted complement-inhibitory therapy may significantly improve outcomes. Case Presentation: A 41-year-old woman (gravida 5, para 3) with a high-risk pregnancy, including a history of preeclampsia complicated by placental abruption and recurrent pregnancy loss, was admitted at 28 weeks' gestation with severe preeclampsia complicated by obstetric TMA. On admission, she presented with hypertension (150/90 mmHg) and proteinuria (1.0 g/day), while hemoglobin, platelet count, and kidney function were within the normal range. On the fourth day of hospitalization, an emergency cesarean section was performed because of progressive placental abruption. The postoperative course was complicated by HELLP syndrome, sepsis, massive hemorrhage, disseminated intravascular coagulation, microangiopathic hemolytic anemia, thrombocytopenia, and severe anuric AKI. Peak laboratory values included hemoglobin 48 g/L, platelet count 48 × 10⁹/L, serum creatinine 563 μmol/L, aspartate aminotransferase 560 U/L, lactate dehydrogenase 5,844 U/L, schistocytes detected on two peripheral blood smears, and a negative direct Coombs test. Despite elimination of the obstetric trigger by delivery, followed by relaparotomy and hysterectomy, TMA manifestations and dialysis-dependent AKI persisted, prompting differential diagnosis between severe HELLP syndrome and aHUS. The patient underwent hemodiafiltration followed by 24 hemodialysis sessions and remained on maintenance hemodialysis for 2.5 months after discharge. Subsequently, kidney function partially recovered, allowing discontinuation of dialysis, although significant renal impairment persisted (serum creatinine 250–300 μmol/L). Conclusion: This case highlights the diagnostic challenge of distinguishing HELLP syndrome from aHUS in obstetric TMA. Persistence of TMA for more than 48–72 hours after removal of the obstetric trigger, together with ongoing microangiopathic hemolysis, thrombocytopenia, and severe AKI, should prompt evaluation for aHUS, including assessment of ADAMTS13 activity, complement abnormalities, and genetic risk factors to guide timely initiation of complement-inhibitory therapy. The case emphasizes the importance of early multidisciplinary management and long-term nephrology follow-up, even in patients who achieve partial recovery of kidney function.